These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22465719)

  • 1. [Going from research to development: which support and financing tools?].
    Roques S
    Presse Med; 2012 May; 41 Suppl 1():S43-5. PubMed ID: 22465719
    [No Abstract]   [Full Text] [Related]  

  • 2. [Presenting a research project on rare diseases to industrial companies].
    Ferry A
    Presse Med; 2012 May; 41 Suppl 1():S38-9. PubMed ID: 22483767
    [No Abstract]   [Full Text] [Related]  

  • 3. Patients often go without effective new treatments, especially in rare disease patient populations where profit potential is limited.
    Bloom BE
    Contemp Clin Trials; 2011 Mar; 32(2):151-2. PubMed ID: 21238613
    [No Abstract]   [Full Text] [Related]  

  • 4. Congress vouches for priority review of childhood disease.
    Palmer R
    Nat Med; 2012 Feb; 18(2):181. PubMed ID: 22310666
    [No Abstract]   [Full Text] [Related]  

  • 5. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The stakes of pre- and post-market authorization development and clinical assessment].
    Schwebig A
    Presse Med; 2012 May; 41 Suppl 1():S6-8. PubMed ID: 22483770
    [No Abstract]   [Full Text] [Related]  

  • 7. [Needs for more R&D in the field of rare diseases].
    Tiennot-Herment L
    Med Sci (Paris); 2018 May; 34 Hors série n°1():48-49. PubMed ID: 29911563
    [No Abstract]   [Full Text] [Related]  

  • 8. [Round table 4. Speeding new therapeutic approaches for rare diseases: do we need new economical models or financial tools?].
    Med Sci (Paris); 2014 Apr; 30 Spe(1):47-53. PubMed ID: 24755179
    [No Abstract]   [Full Text] [Related]  

  • 9. Uncommon ventures launch to tackle uncommon diseases.
    Dolgin E
    Nat Med; 2013 Aug; 19(8):950-1. PubMed ID: 23921728
    [No Abstract]   [Full Text] [Related]  

  • 10. Cuts to the NHMRC budget will undermine the health of all Australians - today and in the future.
    Jennings GL; Macmahon S; Donnan GA
    Med J Aust; 2011 May; 194(9):436-7. PubMed ID: 21534894
    [No Abstract]   [Full Text] [Related]  

  • 11. [France in the European and International research landscape].
    Julkowska D
    Med Sci (Paris); 2018 May; 34 Hors série n°1():55-57. PubMed ID: 29911567
    [No Abstract]   [Full Text] [Related]  

  • 12. [Public partners voices-why do communities support this dynamic?].
    Med Sci (Paris); 2014 Apr; 30 Spe(1):61-2. PubMed ID: 24755182
    [No Abstract]   [Full Text] [Related]  

  • 13. [Development of new indications for old products: difficulties and search for solutions].
    Duguet C
    Presse Med; 2012 May; 41 Suppl 1():S34-6. PubMed ID: 22483765
    [No Abstract]   [Full Text] [Related]  

  • 14. Solving for x: accelerators could speed search for rare disease therapies.
    Wolfson W
    Chem Biol; 2013 Dec; 20(12):1435-7. PubMed ID: 24359846
    [No Abstract]   [Full Text] [Related]  

  • 15. Towards government-funded special biomedical research programs to combat rare diseases in China.
    Chen K; Yao L; Liu Z
    Biosci Trends; 2015 Apr; 9(2):88-90. PubMed ID: 25902953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
    Kumar Kakkar A; Dahiya N
    Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. David Haslam. Interview by Asher Mullard.
    Haslam D
    Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976
    [No Abstract]   [Full Text] [Related]  

  • 18. A new era of hope for the world's most neglected diseases.
    The
    PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rare diseases. Funding programs in Germany and Europe].
    Wetterauer B; Schuster R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):519-28. PubMed ID: 18425694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Financing drug discovery for orphan diseases.
    Fagnan DE; Gromatzky AA; Stein RM; Fernandez JM; Lo AW
    Drug Discov Today; 2014 May; 19(5):533-8. PubMed ID: 24269746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.